In the sensitization phase of contact hypersensitivity in mice, dermal macrophages (MØs) expressing MØ galactose-type C-type lectin1 (MGL1) are known to migrate from the dermis to lymph nodes (LNs) where they accumulate in the subcapsular sinus, interfollicular regions, and areas surrounding high endothelial venules. We hypothesize that the interactions between MGL1 and its ligands determine the localizations of MGL1-positive cells within the LNs. In the present study, our major aim was to isolate MGL1 counter-receptor(s) from lysates of LNs using affinity chromatography with immobilized recombinant MGL1. Fractions bound and eluted with EDTA were analyzed by SDS-PAGE and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. One of the predominant components was sialoadhesin (Sn, Siglec-1). Sn from lysates of LNs was immobilized on microtiter plates precoated with anti-Sn monoclonal antibody, and binding of recombinant MGL1 and adhesion of cells expressing MGL1 were tested. The binding of recombinant MGL1 to Sn was shown to be dependent on Ca 2؉ and N-glycans on Sn. MGL1-transfected Chinese hamster ovary cells adhered to the Sn-coated plates, whereas mock transfectants did not. Immunohistochemical localization of anti-Sn monoclonal antibody in LN coincided with the subcapsular sinus area to which recombinant MGL1 was bound. Furthermore, the distribution of MGL1؉ cells after sensitization with FITC was demonstrated to overlap with that of Sn within the subcapsular sinus of draining LNs. These results suggest that Sn acts as an endogenous counter-receptor for MGL1.
The C-type lectins expressed on cell surfaces in the immune system are known to contribute to recognition and uptake of foreign substances and cellular interactions that determine the localization and activation of the cells. Interactions between lectins and endogenous or exogenous counter-receptors are governed by specific interactions with their carbohydrate ligands presented on protein or lipid carriers (1, 2) . The best-known examples of cellular trafficking controlled by lectin-carbohydrate interactions are those mediated by selectins. Studies on the P-and L-selectin counter-receptor, PSGL-1, clearly demonstrate that C-type lectins can recognize not only the carbohydrate chains but also other structural features on the protein such as sulfated tyrosine residues (3). The combination of both carbohydrate-dependent and -independent molecular interactions between lectins and their counter-receptors can lead to specific, high affinity interactions, despite the fact that the carbohydrate ligands are presented on many different carrier molecules and mediate intrinsically low affinity interactions with lectins (3) .
Macrophage (MØ) 1 galactose (Gal)-type C-type lectins (MGLs) in humans and mice are type II transmembrane glycoproteins having an approximate molecular mass of 42 kDa with a single carbohydrate recognition domain specific for Gal, GalNAc, and Lewis X as mono-or oligosaccharides (4, 5) . MGL was originally purified from tumoricidal MØs, but in mice it is also expressed on a subset of MØs and immature dendritic cells in various lymphoid and connective tissues including thymus, lymph nodes (LNs), spleen, and dermis of the skin (6 -9) . In mice, another Gal-type C-type lectin highly homologous to MGL has been cloned and named Mgl2, and the Mgl previously described was renamed as Mgl1 (5) . These two lectins were shown to have distinct carbohydrate binding specificity. A monoclonal antibody (mAb), LOM-8.7, described previously as a blocking mAb for MGL, was shown to be specific for MGL1 and not to have cross-reactivity for MGL2, whereas LOM-14, a non-blocking mAb for MGL, binds both MGL1 and MGL2 (5, 10, 11) .
Distribution of MGL1/2ϩ cells identified by mAb LOM-14 was unique in murine peripheral LNs. In naive mice, MGL1/2ϩ cells are scattered in the subcapsular sinus and in the medulla except for the center of the T cell area. The number of MGL1/2ϩ cells in regional LNs dramatically increased after epicutaneous sensitization with fluorescein isothiocyanate (FITC) dissolved in a 1/1 mixture of acetone and dibutyl phthalate (AD) solution (FITC/AD) (12) . The number of MGL1/2ϩ cells appeared to correlate with the extent of ear swelling after elicitation at day 8 or later (12) . Intradermal injection of MGL1/2ϩ cells isolated from skin resulted in accumulation of these cells into draining LNs when the skin was sensitized with FITC/AD, suggesting that MGL1/2ϩ cells migrate from the dermis into regional LNs during the sensitization phase in this model of contact hypersensitivity reaction (12) . In sensitized mice, cells reactive with mAb LOM-14 were distributed in the subcapsular sinus, interfollicular regions, areas surrounding HEVs, and the boundary between T and B cell areas at 6 h after sensitization, suggesting that these cells migrated into these regions in LNs. In sections of LNs 24 h after sensitization, numbers of cells reactive with mAb LOM-14 had increased in these areas and also had been detected within T-cell areas, although the number was small. In another experiment using skin explants, epidermal application of AD alone resulted in emigration of MGL1/2ϩ cells from dermis (13) . In this ex vivo experiment, the emigration of MGL1/2ϩ cells from skin explants was shown to be inhibited by treatment with mAb LOM-8.7 specific for MGL1 or anti-interleukin-1␤ mAb (14) . The results of these studies strongly suggest that the interaction between MGL1 and its binding sites regulates the trafficking of MGL1/2ϩ cells from dermis and potentially their distribution within the regional LNs. However, no information was previously available regarding the molecular nature of the ligand-bearing counter-receptors for MGL1.
In the present study, we identified sialoadhesin (Sn, Siglec-1, the first member of the Siglec family) as an endogenous counter-receptor for MGL1 in the subcapsular sinus. The distribution of Snϩ cells in peripheral LNs is restricted to the subcapsular sinus in which the MGL1/2ϩ cells accumulate during the sensitization phase of contact hypersensitivity. We demonstrated that the interaction between MGL1 and Sn was dependent on the carbohydrate-binding activity of MGL1 and the N-linked glycans of Sn. We also demonstrated that Chinese hamster ovary (CHO) cells transfected with MGL1 cDNA adhere to surfaces coated with Sn obtained from LNs.
MATERIALS AND METHODS
Antibodies and Recombinant MGL1-Purified mAb LOM-8.7 (anti-MGL1) (10), mAb 3D6 (anti-Sn), and mAb SER-4 (anti-Sn) (15, 16) were prepared in our laboratory. Recombinant MGL1 was prepared from Escherichia coli transfected with Mgl1 as previously described (17) . To biotinylate these proteins, the proteins were mixed with N-hydroxysuccinimide-biotin (Sigma) dissolved in Me 2 SO (10 mg/ml) for 4 h at room temperature and dialyzed against PBS.
Mice and LN Specimens-Female 6-week-old specific pathogen-free CD-1 (ICR) mice were purchased from Charles River Japan (Yokohama, Japan). They were fed and housed according to the guidelines of the Ministry of Education, Science, Sports and Culture of Japan. The protocols of the animal experiments were approved by the committee in the Graduate School of Pharmaceutical Sciences of the University of Tokyo. In experiments on contact hypersensitivity model, mice anesthetized with diethylether were treated epicutaneously with 40 l of 0.5% FITC (w/v) in a 1:1 mixture of AD on the shaved brachial skin. Brachial LNs at 24 h after sensitization were used.
Histochemical Staining of LN Sections-Brachial LNs were removed, embedded in OCT compound (Miles, Elkhart, IN), and frozen in liquid nitrogen. Cryostat sections (10 m thickness) were prepared and retrieved on poly-L-lysine-coated slides and fixed in acetone. Nonspecific bindings were blocked using a blocking solution (3% BSA in Dulbecco's modified PBS, which was PBS containing 0.91 mM CaCl 2 and 0.49 mM MgCl 2 ) for 10 min at 20°C. To detect MGL1 ligands, the sections were incubated with biotinylated recombinant MGL1 (brMGL1) (10 g/ml) overnight, washed, and further incubated with alkaline phosphataseconjugated streptavidin (1/100 dilution, Vector Laboratories, Burlingame, CA) or Alexa 568-conjugated streptavidin (1/200, Molecular Probes, Eugene, OR) for 30 min. The alkaline phosphatase-stained sections were visualized using HistoMark Red (Kirkegaard & Perry, Gaithersburg, MD), post-fixed in 0.5% glutaraldehyde in Dulbecco's modified PBS for 10 min, and mounted. The serial sections were alternatively stained with mAb 3D6 or mAb SER-4.
In double staining experiments, the sections were first treated with mAb SER-4 or mAb LOM-8.7 at 4°C overnight, washed with Dulbecco's modified PBS three times and subsequently with Cy5-conjugated mouse anti-rat IgG (HϩL) (1/100, Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 h. After washing, the same sections were incubated with brMGL1 or biotinylated mAb SER-4 for 1 h, followed by staining with Alexa 568-conjugated streptavidin. The sections were mounted in PermaFlow (Shandon, Burlingame CA), and observed using a confocal microscope (MRC-1024, Bio-Rad) equipped with a krypton/ argon laser.
Flow Cytometric Analysis-Ligands for MGL1 in peripheral LNs were analyzed using brMGL1 by immunofluorescent staining. The excised and teased LNs (mandibular, brachial, axillary, and inguinal LNs) were incubated in 0.1% collagenase (Wako, Tokyo, Japan), 0.01% DNase in sterile RPMI1640 medium (Invitrogen) containing 10% fetal calf serum (Biowhittaker, Walkersville, MD) (1.6 ml) for 30 min at 37°C. The digested tissue was suspended by pipetting and supplemented with EDTA solution to make a final concentration of 10 mM. They were again incubated for 10 min, mixed by pipetting, and filtered through nylon mesh. Suspended cells were centrifuged twice at 1,000 rpm for 5 min and were resuspended in FCM buffer (PBS containing 0.1% BSA and 0.02% NaN 3 ). In some experiments, cells at low density were concentrated by discontinuous density gradient centrifugation (1,800 rpm, 20 min) on a 45% Percoll solution (Amersham Biosciences).
The cells were incubated with various mAbs for 60 min on ice in the presence of mouse IgG (Zymed Laboratories, Inc.), washed twice with 0.4 ml of FCM buffer, mixed with FITC-conjugated goat anti-mouse IgG (ICN Biomedicals, Irvine, CA) for 30 min, and washed twice with 0.4 ml of FCM buffer. Then the cells were double-stained with brMGL1 (10 g/ml) for 60 min on ice, washed, incubated with phycoerythrin-conjugated streptavidin (BD Biosciences). The cells were analyzed on an Epics Coulter XL flow cytometry system (Coulter, Miami, FL). Data were analyzed using WinMDI software.
Purification of MGL1-binding Proteins-Peripheral LNs were excised from 20 naive mice and homogenized in homogenizing buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10 mM NaN 3 , 2 g/ml aprotinin, 2 g/ml pepstatin, 1 g/ml leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride) using a Dounce-type homogenizer. Homogenates were centrifuged at 9,500 rpm at 4°C for 60 min, and the supernatants were collected and mixed with a CaCl 2 solution to make a final concentration of 20 mM CaCl 2 . The lysates were precleared with Sepharose 4B (Amersham Biosciences) and mixed with 1.5 ml of agarose-avidin D (Vector) previously conjugated with 375 g brMGL1 at 4°C overnight. The agarose beads were packed into a column (Sepacol mini column, Seikagaku Corporation, Tokyo, Japan) and washed with 15 ml of 10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 10 mM NaN 3 , 1 mM CaCl 2 (buffer A) containing 1% Triton X-100 and then were washed with 90 ml of buffer A containing additional 10 mM CHAPS. The bound materials were eluted with 10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 10 mM NaN 3 , 10 mM EDTA, 10 mM CHAPS (buffer B) and collected into 0.3-ml fractions. The protein concentration was measured by the BCA protein assay kit (Pierce). BSA was used as a standard. The fractions eluted with EDTA were subjected to SDS-PAGE followed by Coomassie Brilliant Blue or silver staining. Western blotting analysis with anti-Sn mAbs was also performed. To identify the component bound with MGL1, a portion of the gel with the most prominent band was excised and digested with endoproteinase Lys-C (Roche Applied Science) at 37°C overnight, and the supernatant was analyzed by a matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) (Voyager TM Elite, Applied Biosystems, Foster City, CA). The molecular weight of the digested fragments was compared with a data base in NCBI using ProFound software (The Rockefeller University Edition).
Western and Lectin Blotting Analysis-Purification of Sn from LN lysates with a mAb SER-4-immobilized column were previously described (16) . Samples were suspended and boiled for 5 min with a sample buffer (0.25 M Tris-HCl, pH 6.8, 40% glycerol, 8% SDS, 0.001% bromphenol blue) with or without 1% (v/v) 2-mercaptoethanol (2ME).
Each sample was separated by electrophoresis in 8% polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Immobilon-P, Millipore, Bedford, MA) using the MilliBlot-SDE system (Millipore). After blocking with 5% skim milk (Western blotting) or 3% BSA (lectin blotting) in PBS, the membranes were incubated with 5 g/ml mAb 3D6, biotinylated mAb SER-4, or brMGL1 diluted with Trisbuffered saline (50 mM Tris-HCl, pH 7.5, 150 mM NaCl; TBS) containing 3% BSA, 1 mM CaCl 2 , and 0.1% Tween 20 at 4°C overnight. Negative controls for the staining with antibodies were performed with rat IgG2a (Caltag Laboratories, Burlingame, CA) under the same conditions. The binding was detected by alkaline phosphatase-conjugated goat anti-rat IgG (HϩL) (Zymed Laboratories, Inc., South San Francisco, CA) for mAb 3D6 or alkaline phosphatase-conjugated streptavidin (Vector) for other biotinylated reagents that were diluted 1000 times in TBS containing 3% BSA, 1 mM CaCl 2 , and 0.1% Tween 20. The bound antibodies were visualized by using alkaline phosphatase substrate kit (Vector).
Enzyme-linked Immunosorbent Assay (ELISA)-To immobilize Sn in the MGL1-binding fractions, mAb 3D6 (5 g/ml in PBS) was immobilized to an ELISA plate (Greiner, Frickenhausen, Germany) by adding 50 l/well of the solution and incubated at 4°C overnight. After blocking with 3% BSA in PBS (200 l/well) for 3 h at room temperature, 50 l of fraction 5 (fr. 5) (termed in the first section of the Results section) diluted 10 times in homogenizing buffer containing 10 mM EDTA was added to each well and incubated for 3 h at room temperature. In the case of N-glycosidase F (PNGase F) treatment, fr. 5 was incubated with PNGase F (100 milliunits/l) (Roche Applied Science) for 18 h at 37°C and diluted with homogenizing buffer containing 10 mM EDTA. PNGase F boiled for 10 min was used in the same protocol as a negative control for the enzyme treatment.
The wells were washed three times with TBS containing 1 mM CaCl 2 and with 0.1% Tween 20 to remove unbound materials and then washed with brMGL1 (10 g/ml) or biotinylated mAb SER-4 (2.5 g/ml) diluted in TBS containing 3% BSA, 1 mM CaCl 2 , and 0.1% Tween 20 (50 l/well) was added. Inhibition of brMGL1-binding was tested by replacing the solvent with TBS containing 3% BSA, 10 mM EDTA, and 0.1% Tween 20 (50 l/well) or TBS containing 3% BSA, 1 mM CaCl 2 , 0.1% Tween 20 (50 l/well), and 10 mM Gal. Gal was substituted for mannose as a negative control.
After incubation at 4°C for 2 h, bound brMGL1 or bound biotinylated mAb SER-4 was detected with horseradish peroxidase-conjugated streptavidin (Zymed Laboratories, Inc.) diluted at 1000-fold in TBS containing 1 mM CaCl 2 and 0.1% Tween 20. Subsequently, 1 mM 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt solution in 0.1 M sodium citrate buffer, pH 4.3, containing 0.34% H 2 O 2 was added. Absorbance was measured at 405 nm and 490 nm using a microtiter reader (Model 550, Bio-Rad).
Cell Adhesion Assays in Vitro-Cell adhesion assays were performed by modifying the ELISA system described above by immobilizing purified Sn on plastic plates with mAb 3D6. CHO cells transfected with Mgl1 cDNA or the empty vector (CHO-MGL1 and CHO-mock respectively) were washed with 2 mM EDTA in TBS and suspended in TBS containing 1% BSA and 0.5 mM EDTA (5 ϫ 10 5 cells/ml). The cell suspensions were supplemented with 1 M CaCl 2 in TBS to make a final CaCl 2 concentration at 10 mM , and 50 l each of solution was applied to the well. After incubation at 4°C for 2 h, the wells were washed with TBS containing 1 mM CaCl 2 and observed under phase-contrast microscope (TMD-300, Nikon, Tokyo, Japan). The number of cells adherent to the plates was counted in three fields randomly chosen.
RESULTS

Affinity Isolation of Counter-receptors for MGL1 from
LNs-To identify putative counter-receptors for MGL1 in LNs, affinity chromatography was performed using immobilized brMGL1. Lysates of peripheral LNs from 20 ICR mice were applied to the 1.5 ml of brMGL1 immobilized with agaroseavidin D. The bound materials were eluted with 10 mM EDTA. Among the fractions eluted with EDTA, fr. 5 contained the largest amount of protein (Fig. 1A) . SDS-PAGE analysis under reducing condition followed by silver staining revealed that this fraction contained several components, which potentially corresponded to the counter-receptors for MGL1 in murine peripheral LNs (Fig. 1B) . Among these, a 200-kDa component was the most prominent band after silver staining (Fig. 1B) .
Identification endoproteinase Lys-C. The reaction mixture was applied to a MALDI-TOF MS, and mass numbers of the digested fragments were determined using angiotensin II as a standard. Two mass numbers (1854.89 and 3132.26) of nine submitted to the NCBI data base were matched with those of fragments (amino acids 104 -129 and 1,667-1,683) of Sn, suggesting that the 200-kDa component contained this molecule.
Sn is known to show different migration distance in SDS-PAGE under reducing and non-reducing conditions (16, 18) . As shown in Fig. 2A , migration of the 200-kDa component in fr. 5 shifted to 180 kDa under non-reducing conditions. To further confirm the identity of this 200-kDa component, Western blotting analysis was performed using two anti-Sn mAbs, mAb 3D6 and SER-4, specific for distinct epitopes on Sn (15, 16, 18, 19) . The 200-kDa component was stained strongly with both mAbs 3D6 and SER-4, clearly indicating that the identity of this molecule is Sn (Fig. 2B) . Two other components at relatively high molecular weights were also reactive with these mAbs, suggesting that these might correspond to Sn in oligomeric complexes. The 200-kDa Sn component was reactive with brMGL1 in a lectin blotting analysis (Fig. 2B) . This demonstrated that the isolation of Sn during affinity chromatography was caused by direct binding to MGL1 rather than indirect binding via other component(s). To further confirm the direct binding of brMGL1 to Sn, Sn purified from LN lysates by an affinity column with mAb SER-4 was subjected to the Western blotting analysis with mAb 3D6 under non-reducing conditions. The results revealed that Sn was successfully purified from the lysates (Fig. 2C) . Binding of brMGL1 to purified Sn was clearly demonstrated by lectin blotting and was significantly reduced by treatment with 10 mM Gal (Fig. 2C) . Taken together, these results strongly suggest that Sn is a major counter-receptor for MGL1 in murine peripheral LNs.
MGL1 Binds Sn from Peripheral LNs-The material eluted in fr. 5 from the brMGL1-immobilized columns was treated with PNGase F under reducing (ϩ2ME) and non-reducing (Ϫ2ME) conditions to remove N-glycans. The efficiency of the digestion was monitored by SDS-PAGE and Western blotting analyses with anti-Sn mAbs. After PNGase F treatment under non-reducing conditions, the 200-kDa component migrated to a lower position indicating that the N-glycans were removed at least in part (data not shown).
The PNGase F-treated or untreated material in fr. 5 was added to wells coated with mAb 3D6, and binding of brMGL1 was tested. To normalize the amount of bound brMGL1 to the amount of immobilized Sn, the relative amount of Sn in each well was determined by the binding of mAb SER-4, another anti-Sn mAb. The binding of brMGL1 decreased to 66% of control when N-glycans were removed at least in part (Fig. 3B) . The binding of brMGL1 in the presence of EDTA was 24% of control (Fig. 3B) . This interaction was blocked by the presence of 10 mM Gal (Fig. 3C) . Control experiments as stated under "Materials and Methods" confirmed the specificity of these inhibition experiments (data not shown). Extensive removal of N-glycans by PNGase F treatment seemed to be achieved after reduction with 2ME for 5 min at 100°C and PNGase F treatment. Sn from LNs was shown to be reactive with L-PHA in the blotting assays, and the reactivity was completely abolished by the PNGase F digestion following treatment with 2ME (data not shown). Only very slight reactivity with brMGL1 was detected with this preparation. These results indicated that a significant portion of the interaction between MGL1 and Sn was mediated by N-glycans on Sn through carbohydrate recognition by MGL1. Therefore, we proposed that Sn is a counterreceptor for MGL1 in LNs.
Adhesion of MGL1ϩ Cells to Immobilized Sn-We hypothesize that MGL1ϩ cells that migrate into LNs adhere to Sn present in LNs. To further investigate this possibility, Snmediated adhesion of CHO cells transfected with Mgl1 cDNA was tested. The material in fr. 5 was used to immobilize Sn onto microtiter plates. CHO-MGL1 cells and CHO-mock cells were added to the wells and incubated at 4°C for 2 h. After washing for 5 min at 60 rpm, the adherent cells were counted under a light microscope. Significantly greater numbers of CHO-MGL1 cells adhered to Sn-coated surfaces than did CHOmock cells (Fig. 4, A and B) . No difference was observed in the adhesion of these cells to IgG-coated (Fig. 4B) or untreated plates (data not shown). Adhesion of CHO-MGL1 cells was inhibited by 100 mM Gal (Fig. 4B) but not by mannose at the same concentration (data not shown). These results indicated that the native form of MGL1 expressed on cell surfaces was capable of mediating cell adhesion to Sn.
Immunohistochemical Co-localization and Cytological Identification of Cells Expressing Sn and MGL1 Ligands in LNs-
Histological and flow cytometric analyses were performed to identify cells expressing Sn and ligands for MGL1 in LNs. Frozen sections of mouse LNs were stained with anti-Sn mAb 3D6 and examined under a microscope. The areas stained with this mAb were the subcapsular sinus, interfollicular regions, and the T and B cell boundary (Fig. 5A) . When brMGL1 was used as a histochemical tool, very similar areas were stained (Fig. 5B) . Areas surrounding HEVs were also stained with brMGL1 but not with mAb 3D6. A control antibody or brMGL1 in the presence of EDTA demonstrated only weak staining (Fig.  5, C and D) . In the subcapsular sinus, the co-localization between Sn and the ligand for MGL was further examined by confocal microscopy. Similar profiles regarding the co-localization of Sn and brMGL1-binding sites were observed (Fig. 5G) .
Single cell suspensions were prepared from LNs and examined for the expression of cell surface markers by flow cytometric analysis. In this experiment, cells were double-stained with brMGL1 and mAb 3D6 or mAb for MOMA-1 antigen. The staining profiles of brMGL1-reactive cells for these three antigens are shown in Fig. 5 , H-J. All Snϩ cells and all MOMA-1ϩ cells bound brMGL1. Populations reactive with brMGL1 but not expressing Sn or MOMA-1 antigen were also present in the cell suspension (Fig. 5, H-J) . Most of these were more weakly reactive with brMGL1 than the Snϩ cells, and this is consistent with the numerous weakly stained cells seen in sections of LN (Fig. 5, B and F) . the inner subcapsular sinus (Fig. 6B) , MGL1 expression was less confined and was also found in the outer region of the subcapsular sinus and within the cortex (Fig. 6A) . No differences in staining pattern were seen when mAb LOM-14, which recognizes both MGL1 and MGL2, was used (data not shown). The merged image shows extensive co-localization of Sn and MGL1 within the inner side of the subcapsular sinus (Fig. 6, D  and E) . However, not all MGL1ϩ cells co-expressed Sn, and there appeared to be some MØs that expressed either MGL1 or Sn in close proximity to each other. In LNs from untreated mice, MGL1 was also found to partially co-localize with Sn (data not shown). Neither MGL1ϩ nor Snϩ cells were colocalized with the injected FITC present in the subcapsular sinus (Fig. 6C ). These observations indicated that MGL1ϩ cells and Snϩ cells localized within the subcapsular sinus, which was consistent with our hypothesis that these two molecules participated in the cellular interactions within subcapsular sinus.
Distribution of MGL1ϩ Cells in LNs and
DISCUSSION
Lectins and their carbohydrate ligands expressed on the surfaces of cells in the immune system play essential roles in cell to cell interactions, as clearly demonstrated with selectin family members. Other C-type lectins, particularly those having type II transmembrane configurations, were previously shown to be involved in the uptake of highly glycosylated extracellular macromolecules. Their potential roles in cellular interactions in the immune system are poorly understood, although Geijtenbeek et al. (20) reported that dendritic cellspecific ICAM3-grabbing non-integrin (DC-SIGN) supports tethering and rolling of DC-SIGNϩ cells on the vascular ligand ICAM-2 under shear flow. The present paper proposes that a C-type lectin expressed on MØs, MGL1, endogenously functions as an adhesion molecule via specific interactions with Sn expressed in the subcapsular sinus. MGL1/2ϩ cells, which we tentatively define as histiocytic MØs, migrate from skin to LNs during the sensitization phase of contact hypersensitivity and may play an important regulatory role in immune responses. Our results indicated that these migratory MGL1/2ϩ cells from the skin interact with Snϩ cells in subcapsular sinus, the entrance of regional LNs, though the physiological importance of this interaction remains to be investigated.
We used a biochemical approach of affinity chromatography to initially identify Sn as a potential counter-receptor(s) for MGL1 in LNs and then provided several lines of evidence that clearly demonstrate that MGL1 can mediate highly specific interactions with Sn. First, brMGL1 binds Sn purified from LNs, and this is inhibited by Gal and EDTA and reversed following removal of N-glycans from Sn. Second, immobilized purified Sn can mediate adhesion to MGL1-expressing CHO cells. Third, using recombinant MGL1 as a histochemical probe, we showed that MGL1 ligands and Sn co-localize in the subcapsular sinus of LNs and that MGL1 binding is EDTAsensitive and inhibited by Gal. A potential physiological role for this molecular interaction is supported by our finding that Snϩ MØs and MGLϩ cells are closely apposed to each other in the inner region of the subcapsular sinus.
Sn, also called Siglec-1, is a prototypic member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) and is known to be expressed on specific subsets of tissue MØs (15, 16, 21, 22) . In non-sensitized LNs, Sn expression is restricted to the subcapsular and medullary sinus MØs (15, 23) . Sn is also known to be present on a subpopulation of splenic MØs within the inner marginal zone (24) . Sn is distinct from other Siglecs because of its long extracellular region with 17 Ig-like domains and its short cytoplasmic tail that lacks immunotyrosine inhibitory motifs (19) . A wide variety of studies have shown that Sn can function as a sialic acid-dependent macrophage adhesion molecule for various cells, including those of myeloid and lymphoid origins (24) . However, the results of the present study indicate that sialic acid recognition is not important in the interaction between Sn and MGL1 because bacterially expressed, non-glycosylated MGL was used for most of our studies. It is possible that sialic acid-dependent binding contributes to the interactions between Sn and native MGL1 expressed on infiltrating cells, but this cannot explain the high degree of selectivity of Sn as a counter-receptor for recombinant MGL1 demonstrated here.
An important issue that is raised by our findings is how the MGL1 lectin, which recognizes galactosylated ligands, is able to selectively bind a single major counter-receptor on subcapsular sinus MØs. In general, it might be expected that a large number of different macrophage glycoproteins would carry similar galactosylated ligands, enabling them to act also as counter-receptors. The fact that this was not observed in the present study implies that additional features of Sn besides glycosylation are important in its specific interaction with MGL1. This would be analogous to the recognition of PSGL-1 by the C-type lectin domain of P-selectin, which simultaneously binds to fucose in Lewis X determinants and juxtaposed sulfated tyrosine residues (3). Although the intrinsic nature of MGL1 to form oligomers might assist such multiple interactions, the recombinant MGL1 we used in this study was an extracellular domain of MGL1 expressed in E. coli, which is not likely to form oligomers with increased valency. Further studies are needed to investigate the molecular basis for Sn recognition by MGL1.
Our data raise the question of the nature of the sugars on Sn that are recognized by MGL1. N-glycanase treatment of Sn significantly reduced L-PHA binding and binding of brMGL1. However, it is possible that Sn presents O-linked oligosaccharides that could also contribute to recognition. By the use of glycopeptides, branched complex-type N-glycans terminated with Gal were shown to have high affinity for MGL1. Also, the N-terminal portion of human glycophorin A containing three O-glycans, Gal␤1-3GalNAc or GalNAc, was shown to have high affinity with MGL1 (17) . It was also shown (by the use of soluble polyacrylamide polymers with attached oligosaccharides) that fucosylation of N-acetylglucosamine penultimate to the terminal Gal residues in N-glycans (Lewis X determinants) enhanced the interaction with MGL1 (5). However, the purified Sn did not seem to contain Lewis X determinants based on antibody staining (data not shown).
A glycoform of Sn was shown to serve as a counter-receptor for the cysteine-rich domain (CR) of the macrophage mannose receptor (18) . A soluble form of the CR fused to the Fc region of human IgG recognizes oligosaccharide ligands terminating in GalNAc4-SO 4 , which was demonstrated to be present on specific glycoforms of Sn and CD45 and was responsible for the binding of the Fc region of human IgG to these molecules (18, 25) . The SDS-PAGE profile of brMGL1-binding fractions obtained from LN lysates suggested that MGL1 did not bind the CD45 glycoform, which should migrate at the position corresponding to 100 kDa ( Fig. 1 and Ref. 18) .
The distribution of Sn corresponded to that of MGL1 and MGL1 ligands when the subcapsular sinus in brachial LNs was examined immunohistochemically. This is the area where many MGL1/2ϩ cells were found during the sensitization phase of contact hypersensitivity (12) . Therefore, it is highly likely that MGL1/2ϩ cells in this area are derived from MGL1/2ϩ cells in the dermis, and Snϩ cells capture them after MGL1/2ϩ cells enter into LNs from the afferent lymphatics. Other areas in LNs, such as HEV, were also stained with recombinant MGL1, but these areas were not stained with anti-Sn. There were components other than Sn in lysates of LNs bound and eluted with EDTA from immobilized MGL1 (Fig. 1) . These may represent MGL1 counter-receptors associated with HEV and other areas in LNs. Although Sn is the major silver-stained protein found in eluates from affinity chromatography, silver staining might miss many heavily O-glycosylated proteins that might also interact well with MGL1.
In conclusion, we have demonstrated that a major lymph node counter-receptor for MGL1 is Sn, but the physiological significance of the interaction in regulating the macrophage trafficking remains to be determined. It is also important to determine the role of MGL1/2ϩ cells during the sensitization phase of contact hypersensitivity. Our present work should provide a molecular foundation to address these interesting questions. Whether MGL1 and MGL2 are expressed by identical populations remains to be determined, because most of our previous work and work by other investigators have utilized mAb LOM-14, cross-reactive to both MGL1 and MGL2.
